FDA Brief

Warning letters Devices

FDA warning letter to

Jiangsu Shenli Medical Production Co., Ltd.

High riskIssued Jul 18, 2024Posted Jul 18, 2024Center for Devices and Radiological Health

FDA: Chinese syringe maker Jiangsu Shenli lacked design controls and device master records, halting US imports.

What happened

FDA inspected the Jiangsu Shenli plant in Changzhou, China, from March 25 to 29, 2024, and found the company had no design and development records for its sterile and non-sterile luer lock, luer slip and enteral feeding syringes sold in the US. FDA also found no device master records (the master set of specifications and procedures for making a device) for the company's private label syringes, including syringes with colors, sizes and connection types it never got cleared or approved. FDA said the company's April and May 2024 responses promised corrective actions but gave no evidence they were finished or proven effective.

What FDA found

  1. The company had no design control records at all for its syringe lines, including design input, output, review, verification, validation with risk analysis, transfer, changes, and the design history file.

    21 CFR 820.30(a)(1)
  2. The company had no device master records covering specifications, production processes, quality assurance, packaging and labeling, or servicing for its private label and uncleared syringes.

    21 CFR 820.181
  3. FDA said the company's written responses were not adequate because they did not include completed corrective actions or proof the fixes worked.

What FDA wants

Within 15 business days of receiving the letter, the company must send a written plan of the specific steps taken to fix the violations, how it will prevent them from recurring, and a timetable for any work not yet done, with any non-English documents translated. The company must reply to CDRHWarningLetterResponses@fda.hhs.gov or the listed mailing address, citing CMS case # 687035.

Who should pay attention

  • US distributors and group purchasing organizations that buy these syringes
  • hospitals and clinics that stock private label syringes from Chinese contract manufacturers
  • brands that buy finished product from this contract manufacturer

This is a summary. Read the original letter on fda.gov.

Jiangsu Shenli Medical Production Co., Ltd.'s FDA history

  1. Jiangsu Shenli Medical Production Co., Ltd.

    FDA says Jiangsu Shenli marketed many piston syringes in the U.S. without required clearance or approval.

    High risk

Full company page

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  4. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk